Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

Balance Sheet

Inspect the capital base behind the business.

Assets

$121.74M

FY 2025 · Annual

+2.7% YoY

Liabilities

$42.92M

FY 2025 · Annual

+719.3% YoY

Equity

$78.81M

FY 2025 · Annual

-30.4% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents201.66M3.06M3.17M118.29M98.05M
Short-term Investments46.46M00019.93M
Net Receivables50K0000
Inventory00000
Other Current Assets5.18M3K17K257K78K
Total Current Assets253.35M3.9M3.33M118.55M118.81M
Property, Plant & Equipment (Net)31.29M0001.48M
Goodwill00000
Intangible Assets00000
Long-term Investments852K000499K
Tax Assets00000
Other Non-current Assets1.1M000953K
Total Non-current Assets33.25M0002.93M
Total Assets286.59M3.9M3.33M118.55M121.74M
Account Payables8.36M2.76M2.36M247K1.28M
Short-term Debt6.59M000316K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities15.03M296K540K1.96M6.52M
Total Current Liabilities37.85M5.69M3.94M5.24M9.71M
Long-term Debt03.25M000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities025.23M44.41M032.08M
Total Non-current Liabilities23.48M28.48M44.41M033.21M
Total Liabilities61.33M34.17M48.35M5.24M42.92M
Common Stock7K0002K
Retained Earnings(297.07M)(32.7M)(47.39M)(714.96M)(160M)
Accumulated OCI(155K)00(135K)6K
Other Stockholders Equity00000
Minority Interest00000
Total Equity225.27M(30.27M)(45.02M)113.31M78.81M
Total Debt30.07M3.25M001.45M
Net Debt(171.6M)194K(3.17M)(118.29M)(96.61M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$34.4M
Short-term Investments$62.8M
Other Current$861.0K
Total Current Assets$98.1M
PP&E (Net)$1.4M
Long-term Investments$8.2M
Other Non-current$2.1M
Total Non-current Assets$11.7M
Total Assets$109.8M

Analysis

Selected assets total $109.8M for Latest. The largest visible component is Short-term Investments at $62.8M, about 57.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingOct 26, 2026

How much cash does KLRS have?

Kalaris Therapeutics Inc (KLRS) reported $98.05M in cash and equivalents in fiscal 2025.

How much debt does KLRS carry?

Kalaris Therapeutics Inc (KLRS) reported $1.45M of total debt, with net debt of -$96.61M.